Rolle von T-Zellen bei COPD: Einfluss von Zigarettenrauch-Komponenten auf Differenzierungsprozesse von Th-Subpopulationen

Die chronisch obstruktive Lungenerkrankung (COPD) ist eine weit verbreitete chronisch-entzündliche Erkrankung der Lunge, die mit weltweit steigenden Mortalitätsraten assoziiert ist. Die häufigste Ursache der COPD ist chronische Rauchexposition. Die pathogenen Mechanismen, die zur Ausprägung der Erkr...

Ausführliche Beschreibung

Gespeichert in:
1. Verfasser: Baumgartl, Nadja
Beteiligte: Garn, Holger (PD. Dr. rer. nat.) (BetreuerIn (Doktorarbeit))
Format: Dissertation
Sprache:Deutsch
Veröffentlicht: Philipps-Universität Marburg 2016
Medizin
Ausgabe:http://dx.doi.org/10.17192/z2016.0377
Schlagworte:
Online Zugang:PDF-Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

1. Smith, Michael; Wiggins, John; Barnes, Peter J. (2002): Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. In: Am J Respir Cell Mol Biol 26 (5), S. 602–609.


2. Eunhee S.; Limper, Andrew H. (2010): Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study. In: Respir Res 11 (1), S. 45.


3. Chen K, Pociask DA, McAleer JP, Chan YR, Alcorn JF, Kreindler JL, Keyser MR, Shapiro SD, Houghton AM, Kolls JK, Zheng M (2011) IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS One. 2011; 6(5):e20333.


4. Message, S. et al. (2001): Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. In: Am J Respir Crit Care Med 164 (9), S. 1618–1623.


5. Robbe P1, Spierenburg EA2, Draijer C3, Brandsma CA1, Telenga E4, van Oosterhout AJ5, van den Berge M4, Luinge M1, Melgert BN3, Heederik D2, Timens W1, Wouters IM2, Hylkema MN1. Shifted T-cell polarisation after agricultural dust exposure in mice and men (2014). Thorax. 2014 Jul;69(7):630-


6. Kew, Kayleigh M.; Dias, Sofia; Cates, Christopher J. (2014): Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. In: Cochrane Database Syst Rev 3, S. CD010844.


7. (1994): IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN- gamma. In: J Immunol 153 (9), S. 3989–3996.


8. Manuel E.; Avila, Lydiana; Lasky-Su, Jessica et al. (2009): MMP12, lung function, and COPD in high-risk populations. In: N Engl J Med 361 (27), S. 2599–2608.


9. Bartolome R.; Crim, Courtney et al. (2013): The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. In: Eur Respir J 41 (5), S. 1017–1022.


10. et al. (1998): CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. In: Am J Respir Crit Care Med 157 (3 Pt 1), S. 822–826.


11. Balmes, John; Becklake, Margaret; Blanc, Paul; Henneberger, Paul; Kreiss, Kathleen; Mapp, Cristina et al. (2003): American Thoracic Society Statement: Occupational contribution to the burden of airway disease. In: Am J Respir Crit Care Med 167 (5), S. 787–797.


12. Saetta, M.; Baraldo, S.; Corbino, L.; Turato, G.; Braccioni, F.; Rea, F. et al. (1999): CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. In: Am J Respir Crit Care Med 160 (2), S. 711–717.


13. Langerman, Fawn; Moran, Sienna; Tarragona, Nestor et al. (2010): The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. In: Hum Mol Genet 19 (3), S. 526–534.


14. Sezer, Hafize; Akkurt, Ibrahim; Guler, Nuran; Marakoglu, Kamile; Berk, Serdar (2006): A case-control study on the effect of exposure to different substances on the development of COPD. In: Ann Epidemiol 16 (1), S. 59–62.


15. Celli, Robert J.; Schau, Brigitte (2005): Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. In: Am J Med 118 (12), S. 1364–1372.


16. Barnes, Peter J. (2004): Alveolar macrophages as orchestrators of COPD. In: COPD 1 (1), S. 59–70.


17. Antagonist MK-7123-A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. In: Am J Respir Crit Care Med. (in print)


18. Yoshida, Nozomi et al. (2002): Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. In: Am J


19. Vestbo, J.; Prescott, E.; Lange, P. (1996): Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. In: Am J Respir Crit Care Med 153 (5), S. 1530–1535.


20. Mysliwski, Andrzej (2004): CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. In:


21. Smyth, Lucy J. C.; Starkey, Cerys; Vestbo, Jorgen; Singh, Dave (2007): CD4- regulatory cells in COPD patients. In: Chest 132 (1), S. 156–163.


22. Razani-Boroujerdi, Seddigheh; Singh, Shashi P.; Knall, Cindy; Hahn, Fletcher F.; Pena-Philippides, Juan Carlos; Kalra, Roma et al. (2004): Chronic nicotine inhibits inflammation and promotes influenza infection. In: Cell Immunol 230 (1), S. 1–9.


23. Barnes, P. J.; Shapiro, S. D.; Pauwels, R. A. (2003): Chronic obstructive pulmonary disease: molecular and cellular mechanisms. In: Eur Respir J 22 (4), S. 672–688.


24. Barbro N.; Luinge, Marjan A.; Geerlings, Marie et al. (2006): Cigarette smoke- induced emphysema: A role for the B cell? In: Am J Respir Crit Care Med 173 (7), S. 751–758.


25. Caito, Samuel; Adenuga, David; Rahman, Irfan (2008): Cigarette smoke- mediated inflammatory and oxidative responses are strain-dependent in mice.


26. Bhavani S, Tsai CL, Perusich S, Hesselbacher S, Coxson H, Pandit L, Corry DB, Kheradmand F(2015).Clinical and Immunological Factors in Emphysema Progression. Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD) Am J Respir Crit Care Med. 2015


27. Vestbo, Jorgen (2014): COPD: definition and phenotypes. In: Clin Chest Med 35 (1), S. 1–6.


28. Shirai, Toshihiro; Suda, Takafumi; Inui, Naoki; Chida, Kingo (2010): Correlation between Peripheral Blood T-cell Profiles and Clinical and Inflammatory Parameters in Stable COPD. In: Allergol. Int. 59 (1), S. 75–82.


29. Barczyk, Adam; Pierzchala, Wladyslaw; Kon, Onn M.; Cosio, Borja; Adcock, Ian M.; Barnes, Peter J. (2006): Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. In: J Allergy Clin Immunol 117 (6), S. 1484–1492.


30. Taylor, A. E.; Finney-Hayward, T. K.; Quint, J. K.; Thomas, C. M. R.; Tudhope, S. J.; Wedzicha, J. A. et al. (2010): Defective macrophage phagocytosis of bacteria in COPD. In: Eur Respir J 35 (5), S. 1039–1047.


31. Stockinger, Brigitta; Veldhoen, Marc (2007): Differentiation and function of Th17 T cells. In: Curr Opin Immunol 19 (3), S. 281–286.


32. (2009): Early life origins of chronic obstructive pulmonary disease. In: Thorax 65 (1), S. 14–20.


33. Chen, Ling; Ge, Qi; Tjin, Gavin; Alkhouri, Hatem; Deng, Linghong; Brandsma, Corry-Anke et al. (2014): Effects of cigarette smoke extract on human airway smooth muscle cells in COPD. In: Eur Respir J 44 (3), S. 634–646.


34. Jaoude, Philippe; Honeine, Roland; Akl, Elie A. (2011): Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. In: Chest 139 (4), S. 764–774.


35. Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β2 Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). In: J Med Chem 58(6):2609-22.


36. Silverman, Edwin K.; Demeo, Dawn L. (2010): Gender differences in COPD: are women more susceptible to smoking effects than men? In: Thorax 65 (6), S. 480–485.


37. Amsen, Derk; Spilianakis, Charalampos G.; Flavell, Richard A. (2009): How are T(H)1 and T(H)2 effector cells made? In: Curr Opin Immunol 21 (2), S. 153– 160.


38. (2007): IL-17 Family Cytokines and the Expanding Diversity of Effector T Cell Lineages. In: Annu. Rev. Immunol. 25 (1), S. 821–852.


39. Nakamura, Y.; Levitt, R. C. et al. (2000): IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. In: J Allergy Clin Immunol 105 (1 Pt 1), S. 108–115.


40. McKenzie, N. A. (2000): IL-9-deficient mice establish fundamental roles for IL-9


41. Wang, Huaying; Ying, Huajuan; Wang, Shi; Gu, Xiao; Weng, Yuesong; Peng, Weidong et al. (2014): Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. In: Clin Respir J.


42. Holloway, Rebecca A.; Donnelly, Louise E. (2013): Immunopathogenesis of chronic obstructive pulmonary disease. In: Curr Opin Pulm Med 19 (2), S. 95– 102.


43. Zhang J, Chu S, Zhong X, Lao Q, He Z, Liang Y (2013) Increased expression of CD4+IL-17+ cells in the lung tissue of patients with stable chronic obstructive pulmonary disease (COPD) and smokers.Int Immunopharmacol. 2013 Jan; 15(1):58-66


44. Kwapiszewska, Grazyna; Weisel, Friederike C. et al. (2011): Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. In: Cell 147 (2), S. 293–305.


45. Behndig, Annelie F.; Bucht, Anders; Blomberg, Anders (2009): Influence of Smoking Cessation on Airway T Lymphocyte Subsets in COPD. In: COPD 6 (2),


46. Barnes, Peter J. (2010): Inhaled corticosteroids in COPD: a controversy. In: Respiration 80 (2), S. 89–95.


47. in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. In: Immunity 13 (4), S. 573–583.


48. Takanashi, S.; Hasegawa, Y.; Kanehira, Y.; Yamamoto, K.; Fujimoto, K.; Satoh, K.; Okamura, K. (1999): Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. In: Eur Respir J 14 (2), S. 309–314.


49. Agarwal S, Misra R, Aggarwal A (2008) Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases J Rheumatol. 2008 Mar; 35(3):515-9.


50. Rinaldi, Manuela; Lehouck, An; Heulens, Nele; Lavend'homme, Renaud;


51. Gershon, Andrea S.; Warner, Laura; Cascagnette, Paul; Victor, J. Charles; To, Teresa (2011): Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. In: Lancet 378 (9795), S. 991–996.


52. Tager, I. B.; Ngo, L.; Hanrahan, J. P. (1995): Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. In: Am J Respir Crit Care Med 152 (3), S. 977–983.


53. Tashkin, D. P.; Altose, M. D.; Connett, J. E.; Kanner, R. E.; Lee, W. W.; Wise, R. A. (1996): Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. In: Am J Respir Crit Care Med 153 (6 Pt 1), S. 1802– 1811.


54. Behrendt, Carolyn E. (2005): Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. In: Chest 128 (3), S. 1239–1244.


55. Chung, K. F.; Adcock, I. M. (2008): Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. In: Eur Respir J 31 (6), S. 1334–1356.


56. Stockley, Robert A. (2002): Neutrophils and the pathogenesis of COPD. In: Chest 121 (5 Suppl), S. 151S-155S.


57. Barnes, Peter J. (2013): New anti-inflammatory targets for chronic obstructive pulmonary disease. In: Nat Rev Drug Discov 12 (7), S. 543–559.


58. Barnes, P. J. (2001): New treatments for chronic obstructive pulmonary disease. In: Curr Opin Pharmacol 1 (3), S. 217–222.


59. Barcelo, B.; Pons, J.; Ferrer, J. M.; Sauleda, J.; Fuster, A.; Agusti, A. G. N. (2008): Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. In: Eur Respir J 31 (3), S. 555–562.


60. Anti–Proline-Glycine-Proline or Antielastin Autoantibodies Are Not Evident in Chronic Inflammatory Lung Disease. In: Am J Respir Crit Care Med 181 (1), S. 31–35.


61. Chang, Hua-Chen; Zhang, Shangming; Thieu, Vivian T.; Slee, Roger B.; Bruns, Heather A.; Laribee, R. Nicholas et al. (2005): PU.1 expression delineates heterogeneity in primary Th2 cells. In: Immunity 22 (6), S. 693–703.


62. Dasgupta, Alakananda; Saxena, Renu (2012): Regulatory T cells: a review. In:


63. Watz H, Mistry SJ, Lazaar AL (2013): Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. In: Pulm Pharmacol Ther (5):588-95.


64. Seder, Robert A.; Ahmed, Rafi (2003): Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. In: Nat Immunol 4 (9), S. 835– 842.


65. Smoke exposure as a determinant of autoantibody titre in alpha(1)-antitrypsin deficiency and COPD. In: Eur Respir J 37 (1), S. 32–38.


66. Prescott, E.; Vestbo, J. (1999): Socioeconomic status and chronic obstructive pulmonary disease. In: Thorax 54 (8), S. 737–741.


67. (2013): Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases. In: Ann N Y Acad Sci.1280:35-9.


68. Kemeny, D. M.; Vyas, B.; Vukmanovic-Stejic, M.; Thomas, M. J.; Noble, A.; Loh, L. C.; O'Connor, B. J. (1999): CD8(+) T cell subsets and chronic obstructive pulmonary disease. In: Am J Respir Crit Care Med 160 (5 Pt 2), S. S33-7.


69. Barnes, Peter J. (2009): The cytokine network in chronic obstructive pulmonary disease. In: Am J Respir Cell Mol Biol 41 (6), S. 631–638.


70. Cazzola M, Lopez-Campos JL, Puente-Maestu L. (2013): The MABA approach: a new option to improve bronchodilator therapy. In: Eur Respir J;42(4):885-7.


71. Stritesky, Gretta L. et al. (2010): The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. In: Nat Immunol 11 (6), S. 527–534.


72. Salvi, Sundeep (2014): Tobacco smoking and environmental risk factors for chronic obstructive pulmonary disease. In: Clin Chest Med 35 (1), S. 17–27.


73. L.; O'Connor, G. T. (1996): Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. In: Am J


74. yl)ethyl)amino)methyl)-5 methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-


75. Lofdahl, Claes-Goran; Wachenfeldt, Karin von (2006): Cigarette smoke extract modulates respiratory defence mechanisms through effects on T-cells and airway epithelial cells. In: Respir Med 100 (5), S. 818–827.


76. Christopher S. Stevenson, Jonas S. Erjefält, and Martin R. Stampfli "IL-17A and the Promotion of Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease"(2015), American Journal of Respiratory and Critical Care Medicine, Vol. 192, No. 4 (2015), pp. 428-437.


77. Calverley, Peter M. A.; Rabe, Klaus F.; Goehring, Udo-Michael; Kristiansen, Soren; Fabbri, Leonardo M.; Martinez, Fernando J. (2009): Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. In: Lancet 374 (9691), S. 685–694.


78. Westendorf, Astrid; Buer, Jan et al. (2008): Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9- producing subset. In: Nat Immunol 9 (12), S. 1341–1346.


79. Barnes, P. J. (2000): Chronic obstructive pulmonary disease. In: N Engl J Med 343 (4), S. 269–280.


80. Larminie C, Singh D. (2015): Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial. In: Pharmacol Res Perspect3(1):e00094.


81. Temann, Ulla-Angela; Ray, Prabir; Flavell, Richard A. (2002): Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. In: J Clin Invest 109 (1), S. 29–39.


82. O. (1991): Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. In: BMJ 303 (6804), S. 671–675.


83. Grashoff, W. F.; Sont, J. K.; Sterk, P. J.; Hiemstra, P. S.; Boer, W. I. de; Stolk, J. et al. (1997): Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. In: Am J Pathol 151 (6), S. 1785–1790.


84. Barnes, Peter J. (2007): Chronic obstructive pulmonary disease: a growing but neglected global epidemic. In: PLoS Med 4 (5), S. e112.


85. Temann, U. A.; Geba, G. P.; Rankin, J. A.; Flavell, R. A. (1998): Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. In: J Exp Med 188 (7), S. 1307–1320.


86. Barnes, Peter J. (2008): The cytokine network in asthma and chronic obstructive pulmonary disease. In: J. Clin. Invest. 118 (11), S. 3546–3556.


87. Charles S. (2006): Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. In: Am J Respir Crit Care Med 173 (9), S. 991–998.


88. William M. et al. (2009): Marijuana and chronic obstructive lung disease: a population-based study. In: CMAJ 180 (8), S. 814–820.


89. Azimzadeh, Agnes; Nadler, Steven G. et al. (2008): CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis. In: J Immunol 181 (3), S. 1806–1813.


90. Stephen L.; Kaplan, Mark H. (2009): PU.1 regulates TCR expression by modulating GATA-3 activity. In: J Immunol 183 (8), S. 4887–4894.


91. Goswami, Ritobrata; Kaplan, Mark H. (2011): A brief history of IL-9. In: J Immunol 186 (6), S. 3283–3288.


92. Jabeen, Rukhsana; Goswami, Ritobrata; Awe, Olufolakemi; Kulkarni, Aishwarya; Nguyen, Evelyn T.; Attenasio, Andrea et al. (2013): Th9 cell development requires a BATF-regulated transcriptional network. In: J Clin Invest 123 (11), S. 4641–4653.


93. Holt, P. G. (1987): Immune and inflammatory function in cigarette smokers. In: Thorax 42 (4), S. 241–249.


94. Huh, Joseph et al. (2004): An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. In: PLoS Med 1 (1), S. e8.


95. Carlier, Vincent; Saint-Remy, Jean-Marie et al. (2012): Antielastin B-cell and T- cell immunity in patients with chronic obstructive pulmonary disease. In: Thorax 67 (8), S. 694–700.